Cochlear Ltd - Asset Resilience Ratio
Cochlear Ltd (COH) has an Asset Resilience Ratio of 9.76% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Cochlear Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Cochlear Ltd's Asset Resilience Ratio has changed over time. See COH equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Cochlear Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see COH market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$275.70 Million | 9.76% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$275.70 Million | 9.76% |
Asset Resilience Insights
- Limited Liquidity: Cochlear Ltd maintains only 9.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Cochlear Ltd Industry Peers by Asset Resilience Ratio
Compare Cochlear Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Respiri Ltd
AU:RSH |
Medical Devices | 0.46% |
|
Human Xtensions Ltd
TA:HUMX |
Medical Devices | 29.83% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Cochlear Ltd (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Cochlear Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 9.76% | AU$275.70 Million ≈ $195.08 Million |
AU$2.83 Billion ≈ $2.00 Billion |
-12.69pp |
| 2024-06-30 | 22.45% | AU$616.30 Million ≈ $436.07 Million |
AU$2.75 Billion ≈ $1.94 Billion |
-2.71pp |
| 2023-06-30 | 25.16% | AU$646.30 Million ≈ $457.30 Million |
AU$2.57 Billion ≈ $1.82 Billion |
-3.16pp |
| 2022-06-30 | 28.32% | AU$698.10 Million ≈ $493.95 Million |
AU$2.47 Billion ≈ $1.74 Billion |
+2.07pp |
| 2021-06-30 | 26.25% | AU$636.90 Million ≈ $450.65 Million |
AU$2.43 Billion ≈ $1.72 Billion |
-9.75pp |
| 2020-06-30 | 36.00% | AU$930.00 Million ≈ $658.03 Million |
AU$2.58 Billion ≈ $1.83 Billion |
+3.84pp |
| 2019-06-30 | 32.16% | AU$443.60 Million ≈ $313.88 Million |
AU$1.38 Billion ≈ $975.87 Million |
+26.53pp |
| 2018-06-30 | 5.64% | AU$65.20 Million ≈ $46.13 Million |
AU$1.16 Billion ≈ $818.58 Million |
-3.87pp |
| 2017-06-30 | 9.50% | AU$107.97 Million ≈ $76.40 Million |
AU$1.14 Billion ≈ $804.00 Million |
+8.31pp |
| 2016-06-30 | 1.20% | AU$11.45 Million ≈ $8.10 Million |
AU$957.36 Million ≈ $677.40 Million |
+0.76pp |
| 2015-06-30 | 0.44% | AU$3.85 Million ≈ $2.73 Million |
AU$875.40 Million ≈ $619.40 Million |
+0.41pp |
| 2010-06-30 | 0.03% | AU$204.00K ≈ $144.34K |
AU$751.72 Million ≈ $531.89 Million |
-- |
About Cochlear Ltd
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor… Read more